Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Pfizer pulls all lots of sickle cell disease drug
Pharmalittle: We’re reading about Pfizer pulling a sickle cell pill, Moderna getting scolded, and more
Pfizer is removing its Oxbryta pill for sickle cell disease from all markets globally due to safety risks, including deaths.
Pfizer pulls all lots of sickle cell disease drug from market
Pfizer has announced the withdrawal of all lots of Oxbryta, its drug for sickle cell disease, amid concerns about increased complications and fatal events. The decision, effective immediately in all approved markets,
Deaths lead Pfizer to pull sickle cell drug at center of $5 billion Bay Area buyout
Pfizer had big hopes for a sickle-cell disease drug, as did those suffering from the disease. Things didn't turn out as planned.
4d
on MSN
Pfizer v Moderna COVID vaccine patents battle to go to appeal in UK
Pfizer and Moderna's legal battle over their rival COVID-19 vaccines will continue after London's High Court on Wednesday ...
PMLiVE
4d
Pfizer/BioNTech’s KP.2-adapted COVID-19 vaccine receives CHMP recommendation
Pfizer and BioNTech’s updated COVID-19 vaccine targeting the KP.2 strain, a descendant of JN.1, has been recommended by the ...
10d
on MSN
BioNTech Is More Than a Covid-19 Stock. It’s Having a Great September.
BioNTech has been boosted a wave of enthusiasm over another company’s cancer drug, which has turned the biopharma industry ...
5d
Updated Pfizer-BioNTech’s COVID-19 vaccine approved by Health Canada
Health Canada approved Pfizer-BioNTech’s updated COVID-19 vaccine on Tuesday, marking its third authorization of vaccine ...
5d
Pfizer Canada and BioNTech Receive Health Canada Approval of Omicron KP.2 Variant Adapted COVID-19 Vaccine
Pfizer Canada ULC and BioNTech SE (Nasdaq: BNTX, "BioNTech") announced today that Health Canada has authorized the KP.2 ...
4d
Pfizer’s Investment Outlook: A Cautious Hold Amid Oxbryta Withdrawal and Mixed Acquisition Results
In a report released today, Carter Gould from Barclays maintained a Hold rating on Pfizer (PFE – Research Report), with a price target of ...
EuropaWire
9d
Pfizer and BioNTech’s Omicron KP.2-Adapted COVID-19 Vaccine Receives Positive EU Opinion, Awaiting Approval
Pfizer and BioNTech’s Omicron KP.2-adapted COVID-19 vaccine has received a positive recommendation from the European ...
9d
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron KP.2-adapted COVID-19 Vaccine in the European Union
Pfizer Inc. (NYSE: PFE, "Pfizer") and BioNTech SE (Nasdaq: BNTX, "BioNTech") today announced that the Committee for Medicinal ...
Business Insider
4d
Pfizer’s Hold Rating: Evaluating the Impact of Oxbryta Withdrawal and Pipeline Uncertainties
While
Pfizer
is developing a next-generation version of Oxbryta ... Flynn covers the Healthcare sector, focusing on stocks such as
BioNTech
SE, Eli Lilly & Co, and Regeneron. In another report ...
13d
on MSN
Is Pfizer Stock Going to $36? 1 Wall Street Analyst Thinks So.
The company's best days as a top pandemic vaccine supplier might be over, but it still has enough potential to be compelling.
5d
Pfizer's updated COVID-19 vaccine approved, Health Canada says
Pfizer-BioNTech's updated vaccine to protect against a recently circulating variant of COVID-19 is authorized, Health Canada said on Tuesday.
19h
Novo Nordisk's Ozempic, Regeneron/Sanofi's Dupixent set to advance in top drug sales
AbbVie Humira, Pfizer/BioNTech COVID-19 shot may not make top 10 pharma drugs in 2024, with Novo Nordisk Ozempic and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback